NEW YORK (GenomeWeb News) – Genomind today announced a partnership with Emory University to commercialize a blood-based screening test for mild cognitive impairment and Alzheimer's disease.
Under the terms of the deal, Genomind has attained the exclusive rights to commercialize blood-based protein biomarkers for assessment of the conditions. Other terms of the agreement were not disclosed.
"The development of this test represent one of the most significant efforts to date in making available a simple screening tool for mild cognitive impairment and Alzheimer's disease," Jay Lombard, chief scientific officer and medical director of Genomind, said in a statement. "But even more importantly, this joint effort between Genomind and Emory will allow us to consider preventive approaches for those at highest risk of developing Alzheimer's disease."
According to the Chalfont, Pa.-based company, more than 5 million Americans live with Alzheimer's, which is the sixth leading cause of death in the US.